IN THE NEWS
Heading 2
Heading 2
21 March 2025
Rostra Therapeutics at the Edinburgh AMR Forum Lecture
John Mulgrew, co-founder of Rostra Therapeutics, recently attended the Edinburgh AMR Forum Lecture: Inventing an Anti-Infective Drug. The event brought together researchers, clinicians, and innovators focused on addressing the growing challenge of antimicrobial resistance (AMR).
The lecture offered valuable insights into the scientific, regulatory, and commercial pathways required to bring new anti-infective therapies to patients. As a company committed to advancing novel treatments for serious infections, Rostra was pleased to be part of this important discussion.
We’re grateful to the Edinburgh AMR Forum for hosting such a thought-provoking event and look forward to continued collaboration within the UK’s vibrant AMR research and innovation community.
Heading 2
26 February 2025
Rostra Therapeutics at the 9th AMR Conference in Basel
Rostra Therapeutics at the 9th AMR Conference in Basel
We were pleased to be represented at the 9th annual AMR Conference in Basel, Switzerland, by our cofounder, David Findlay. The event brought together global leaders in antimicrobial resistance (AMR) to explore innovative science, collaborative strategies, and investment opportunities aimed at tackling one of the most urgent public health threats of our time.
David engaged with partners across industry, academia, and policy, highlighting Rostra Therapeutics’ commitment to developing novel anti-infective therapies, including our lead work in antifungal drug development. The conference served as an excellent platform to share insights, build strategic relationships, and stay connected to the evolving AMR innovation ecosystem.
We remain inspired by the momentum in the AMR space and look forward to contributing to the global effort to advance impactful solutions.
Heading 2
13 November 2024
Rostra Therapeutics awarded share of £3m Cystic Fibrosis Collaborative Drug Discovery Programme
Rostra Therapeutics are delighted to be one of the companies to be awarded a share of a £3 million Collaborative Discovery Programme (CDP) announced by the Cystic Fibrosis Antimicrobial Resistance (CF AMR) Syndicate. The CF AMR Syndicate is a cross-sector initiative that brings together leading experts in Cystic Fibrosis (CF) and Antimicrobial Resistance (AMR) from industry, academia and the clinic, along with insights from people living with CF, to accelerate the discovery and development of new and effective treatment options for people with CF.
​
Heading 2
25 September 2024
New Board Appointment
We are delighted to announce that Professor Colin Suckling OBE has become a member of the Board and shareholder of Rostra Therapeutics, and to confirm his position as permanent CSO. As a former Vice Principal, Dean of the Faculty of Science, and Head of the Department of Pure & Applied Chemistry at the University of Strathclyde, Colin brings a wealth of experience in supporting and managing research, in particular in delivering novel molecular structures to help combat diseases threats, including being a co-inventor of the Strathclyde Minor Groove Binders (S-MGBs). We look forward to working with Colin to advance our technology towards medicines that will help to address the global threat of Infectious Disease and Antimicrobial Resistance
11 Sep 2023
Rostra Therapeutics selected for Scale Up Scotland workshop hosted by the Hunter Foundation
​
The Scale-up Scotland leadership programme is a cohort-based programme aimed at ambitious entrepreneurs and firms with the potential and desire to grow and scale their businesses. This programme is results-oriented, delivered and supported by leading entrepreneurs, expert business practitioners and facilitators.
08 August 2023
Rostra Therapeutics attends Antimicrobial Resistance workshop hosted by CIFAR in Toronto, Canada
​
Our CEO, David Findlay, was delighted to be invited to attend a Canadian Institute for Advanced Research (CIFAR) meeting in Toronto earlier this year. Titled 'Catalyzing the Development of Fungicides and Antifungal Drugs: Challenges and Opportunities', the workshop addressed many key issues around the discovery and development of new antifungals at a time when there are limited fungicidal and therapeutic choices, many of which are becoming increasingly compromised by the increase in antimicrobial resistance (AMR). Among the workshop attendees were academics, clinicians, public health, regulators, funders and industry representatives, leading to broad ranging discussions and the initiation of a set of recommendations to further support discovery and development in this critical area
.png)
